4.5 Article

NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases

期刊

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 28, 期 2, 页码 214-221

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2017.10.074

关键词

Metallo-beta-lactamase; NDM-1 inhibitor; Cyclic dithiocarbamate; Antibiotic resistance

资金

  1. NSFC - China [U1204206, 81501782, 21702190]
  2. 863 Program - China [2015AA020911]
  3. Henan Province - China [17A350004, 152300410034]

向作者/读者索取更多资源

The emergence of antibiotic drug (like carbapenem) resistance is being a global crisis. Among those resistance factors of the beta-lactam antibiotics, the metallo-beta-lactamases (MBLs) is one of the most important reasons. In this paper, a series of cyclic dithiocarbamate compounds were synthesized and their inhibition activities against MBLs were initially tested combined with meropenem (MEM) by in vitro antibacterial efficacy tests. Sodium 1,4,7-triazonane-1,4,7-tris(carboxylodithioate) (compound 5) was identified as the most active molecule to restore the activity of MEM. Further anti-bacterial effectiveness assessment, compound 5 restored the activity of MEM against Escherichia coli, Citrobacter freundii, Proteus mirabilis and Klebsiella pneumonia, which carried resistance genes of blaNDM-1. The compound 5 was non-hemolytic, even at a concentration of 1000 mu g/mL. This compound was low toxic toward mammalian cells, which was confirmed by fluorescence microscopy image and the inhibition rate of HeLa cells. The Ki value of compounds 5 against NDM-1 MBL was 5.63 +/- 1.27 mu M. Zinc ion sensitivity experiments showed that the inhibitory effect of compound 5 as a MBLs inhibitor was influenced by zinc ion. The results of the bactericidal kinetics displayed that compound 5 as an adjuvant assisted MEM to kill all bacteria. These data validated that this NOTA dithiocarbamate analogue is a good inhibitor of MBLs. (C) 2017 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据